Top

Published in:

01-08-2004 | Review

Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D₃ analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies

Authors: R. N. J. de Nijs, J. W. G. Jacobs, A. Algra, W. F. Lems, J. W. J. Bijlsma

Published in: Osteoporosis International | Issue 8/2004

Abstract

The aim of this review with meta-analysis was to determine if there is a rationale to use activated forms of vitamin D₃ to treat or prevent glucocorticoid-induced osteoporosis, and to compare the effect of active vitamin D₃ metabolites with that of other anti-osteoporosis therapies. We performed a systemic search using MEDLINE/PubMed (1966–2003). Animal studies and clinical trials involving humans with data on therapy to treat or prevent glucocorticoid-induced osteoporosis with active vitamin D₃ analogues were included. Animal studies and basic research studies with active vitamin D₃ were reviewed (qualitative review). Meta-analysis (quantitative review) on clinical trials (including organ transplantation studies) was performed with percent change in lumbar spine bone mineral density or bone mineral content as the primary outcome measure; the secondary outcome measure was incidence of vertebral fractures. Fifty-four articles were found. Animal and basic research studies showed that active vitamin D₃ analogues can inhibit bone loss during treatment with glucocorticoids. Concerning the effect on bone mineral density, the pooled effect size of active vitamin D₃ analogues compared with no treatment, placebo, plain vitamin D₃ and/or calcium was 0.35 (95% confidence interval (CI) 0.18, 0.52). Compared with bisphosphonates, the pooled effect size was −1.03 (95% CI −1.71, −0.36). The pooled estimate of the relative risk for vertebral fractures of active vitamin D₃ analogues compared with no treatment, placebo, plain vitamin D₃ and/or calcium was 0.56 (95% CI 0.34, 0.92) and compared with bisphosphonates it was 1.20 (95% CI 0.32, 4.55). Active vitamin D₃ analogues not only preserve bone during glucocorticoid therapy more effectively than no treatment, placebo, plain vitamin D₃ and/or calcium, but are also more effective in decreasing the risk of vertebral fractures. Bisphosphonates, however, are more effective in preserving bone and decreasing the risk of vertebral fractures than active vitamin D₃ analogues.

Lukert BP, Raisz LG (1990) Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 112:352–364

Adachi JD, Bensen WG, Hodsman AB (1993) Corticosteroid-induced osteoporosis. Semin Arthritis Rheum 22:375–384

de Nijs RN, Jacobs JW, Bijlsma JW, Lems WF, Laan RF, Houben HH et al. (2001) Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis. Rheumatology (Oxford) 40:1375–1383

Klein RG, Arnaud SB, Gallagher JC, DeLuca HF, Riggs BL (1977) Intestinal calcium absorption in exogenous hypercortisonism. Role of 25-hydroxyvitamin D and corticosteroid dose. J Clin Invest 60:253–259PubMed

Hahn TJ, Halstead LR, Baran DT (1981) Effects of short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. J Clin Endocrinol Metab 52:111–115PubMed

Aloia JF, Semla HM, Yeh JK (1984) Discordant effects of glucocorticoids on active and passive transport of calcium in the rat duodenum. Calcif Tissue Int 36:327–331PubMed

Suzuki Y, Ichikawa Y, Saito E, Homma M (1983) Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 32:151–156CrossRefPubMed

Rubin MR, Bilezikian JP (2002) Clinical review 151: the role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. J Clin Endocrinol Metab 87:4033–4041CrossRefPubMed

Patschan D, Loddenkemper K, Buttgereit F (2001) Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone 29:498–505CrossRefPubMed

10.

Gronowicz GA, McCarthy MB (1995) Glucocorticoids inhibit the attachment of osteoblasts to bone extracellular matrix proteins and decrease beta 1-integrin levels. Endocrinology 136:598–608PubMed

11.

Akeno N, Matsunuma A, Maeda T, Kawane T, Horiuchi N (2000) Regulation of vitamin D-1-alpha-hydroxylase and -24-hydroxylase expression by dexamethasone in mouse kidney. J Endocrinol 164:339–348PubMed

12.

Dykman TR, Gluck OS, Murphy WA, Hahn TJ, Hahn BH (1985) Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthr Rheum 28:361–368

13.

Reid IR, Heap SW (1990) Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Int Med 150:2545–2548CrossRef

14.

Verstraeten A, Dequeker J (1986) Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids. Ann Rheum Dis 45:852–857PubMed

15.

Michel BA, Bloch DA, Wolfe F, Fries JF (1993) Fractures in rheumatoid arthritis: an evaluation of associated risk factors. J Rheumatol 20:1666–1669PubMed

16.

Laan RF, van Riel PL, van Erning LJ, Lemmens JA, Ruijs SH, van de Putte LB (1992) Vertebral osteoporosis in rheumatoid arthritis patients: effect of low dose prednisone therapy. Br J Rheumatol 31:91–96PubMed

17.

van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000PubMed

18.

Gough AK, Lilley J, Eyre S, Holder RL, Emery P (1994) Generalised bone loss in patients with early rheumatoid arthritis. Lancet 344:23–27PubMed

19.

Jones SM, Bhalla AK (1993) Osteoporosis in rheumatoid arthritis. Clin Exp Rheumatol 11:557–562PubMed

20.

Roux C, Abitbol V, Chaussade S, Kolta S, Guillemant S, Dougados M et al. (1995) Bone loss in patients with inflammatory bowel disease: a prospective study. Osteoporos Int 5:156–160PubMed

21.

Epstein S, Shane E, Bilezikian JP (1995) Organ transplantation and osteoporosis. Curr Opin Rheumatol 7:255–261PubMed

22.

Reichel H, Koeffler HP, Norman AW (1989) The role of the vitamin D endocrine system in health and disease. N Engl J Med 320:980–991

23.

Hahn TJ, Halstead LR, Teitelbaum SL, Hahn BH (1979) Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration. J Clin Invest 64:655–665PubMed

24.

Koike N, Ichikawa F, Nishii Y, Stumpf WE (1998) Sustained osteoblast nuclear receptor binding of converted 1-alpha, 25-dihydroxyvitamin D₃ after administration of ³H-1-alpha-hydroxyvitamin D₃: a combined receptor autoradiography and radioassay time course study with comparison to ³H-1alpha, 25-dihydroxyvitamin D₃. Calcif Tissue Int 63:391–395CrossRefPubMed

25.

Bikle DD (1994) Role of vitamin D, its metabolites, and analogs in the management of osteoporosis. Rheum Dis Clin N Am 20:759–775

26.

Shiraishi A, Takeda S, Masaki T, Higuchi Y, Uchiyama Y, Kubodera N et al. (2000) Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. J Bone Miner Res 15:770–779PubMed

27.

Sato F, Ouchi Y, Okamoto Y, Kaneki M, Nakamura T, Ikekawa N et al. (1991) Effects of vitamin D₂ analogs on calcium metabolism in vitamin D-deficient rats and in MC3T3-E1 osteoblastic cells. Res Exp Med (Berl) 191:235–242

28.

Müller K, Haahr PM, Diamant M, Rieneck K, Kharazmi A, Bendtzen K (1992) 1,25-dihydroxyvitamin D₃ inhibits cytokine production by human blood monocytes at the post-transcriptional level. Cytokine 4:506–512PubMed

29.

Norman AW, Sergeev IN, Bishop JE, Okamura WH (1993) Selective biological response by target organs (intestine, kidney, and bone) to 1,25-dihydroxyvitamin D₃ and two analogues. Cancer Res 53:3935–3942PubMed

30.

Lems WF, van Veen GJ, Gerrits MI, Jacobs JW, Houben HH, van Rijn HJ et al. (1998) Effect of low-dose prednisone (with calcium and calcitriol supplementation) on calcium and bone metabolism in healthy volunteers. Br J Rheumatol 37:27–33CrossRefPubMed

31.

Qaw F, Calverley MJ, Schroeder NJ, Trafford DJ, Makin HL, Jones G (1993) In vivo metabolism of the vitamin D analog, dihydrotachysterol. Evidence for formation of 1 alpha,25- and 1 beta,25-dihydroxy-dihydrotachysterol metabolites and studies of their biological activity. J Biol Chem 268:282–292PubMed

32.

Fraser DR (1995) Vitamin D. Lancet 345:104–107CrossRefPubMed

33.

Heikkinen A, Parviainen MT, Tuppurainen MT, Niskanen L, Komulainen MH, Saarikoski S (1998) Effects of postmenopausal hormone replacement therapy with and without vitamin D₃ on circulating levels of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D. Calcif Tissue Int 62:26–30CrossRefPubMed

34.

Heaney RP, Recker RR, Stegman MR, Moy AJ (1989) Calcium absorption in women: relationships to calcium intake, estrogen status, and age. J Bone Miner Res 4:469–475PubMed

35.

Warady BD, Lindsley CB, Robinson FG, Lukert BP (1994) Effects of nutritional supplementation on bone mineral status of children with rheumatic diseases receiving corticosteroid therapy. J Rheumatol 21:530–535PubMed

36.

Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM (1996) Calcium and vitamin D₃ supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 125:961–968PubMed

37.

Talalaj M, Gradowska L, Marcinowska-Suchowierska E, Durlik M, Gaciong Z, Lao M (1996) Efficiency of preventive treatment of glucocorticoid-induced osteoporosis with 25-hydroxyvitamin D₃ and calcium in kidney transplant patients. Transplant Proc 28:3485–3487PubMed

38.

Review Manager (RevMan) Computer program Version 4.2.2 for Windows (2003) Oxford, England. The Cochrane Collaboration

39.

Dykman TR, Haralson KM, Gluck OS, Murphy WA, Teitelbaum SL, Hahn TJ et al. (1984) Effect of oral 1,25-dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 27:1336–1343

40.

Cueto-Manzano AM, Konel S, Freemont AJ, Adams JE, Mawer B, Gokal R et al. (2000) Effect of 1,25-dihydroxyvitamin D₃ and calcium carbonate on bone loss associated with long-term renal transplantation. Am J Kidney Dis 35:227–236PubMed

41.

Dequeker J, Borghs H, Van Cleemput J, Nevens F, Verleden G, Nijs J (2000) Transplantation osteoporosis and corticosteroid-induced osteoporosis in autoimmune diseases: experience with alfacalcidol. Z Rheumatol 59 (Suppl 1):53–57CrossRef

42.

Lakatos P, Nagy Z, Kiss L, Horvath C, Takacs I, Foldes J et al. (2000) Prevention of corticosteroid-induced osteoporosis by alfacalcidol. Z Rheumatol 59 (Suppl 1):48–52CrossRefPubMed

43.

Neubauer E, Neubauer N, Ritz E, Dreikorn K, Krause KH (1984) Bone mineral content after renal transplantation. Placebo-controlled prospective study with 1,25-dihydroxy vitamin D₃. Klin Wochenschr 62:93–96PubMed

44.

Neuhaus R, Kubo A, Lohmann R, Rayes N, Hierholzer J, Neuhaus P (1999) Calcitriol in prevention and therapy of osteoporosis after liver transplantation. Transplant Proc 31:472–473PubMed

45.

Braun JJ, Birkenhager-Frenkel DH, Rietveld AH, Juttmann JR, Visser TJ, Birkenhager JC (1983) Influence of 1 alpha-(OH)D₃ administration on bone and bone mineral metabolism in patients on chronic glucocorticoid treatment; a double blind controlled study. Clin Endocrinol (Oxf) 19:265–273

46.

Briner VA, Thiel G, Monier-Faugere MC, Bognar B, Landmann J, Kamber V et al. (1995) Prevention of cancellous bone loss but persistence of renal bone disease despite normal 1,25 vitamin D levels two years after kidney transplantation. Transplantation 59:1393–1400PubMed

47.

Shane E, Rodino MA, McMahon DJ, Addesso V, Staron RB, Seibel MJ et al. (1998) Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study. J Heart Lung Transplant 17:1089–1096PubMed

48.

Sivri A, Karaduman A, Gokce-Kutsal Y, Atakan N (2002) Calcitriol treatment of glucocorticoid-induced osteoporosis in subjects with pemphigus vulgaris. J Eur Acad Dermatol Venereol 16:89–91CrossRefPubMed

49.

Riemens SC, Oostdijk A, van Doormaal JJ, Thijn CJ, Drent G, Piers DA et al. (1996) Bone loss after liver transplantation is not prevented by cyclical etidronate, calcium and alphacalcidol. The Liver Transplant Group, Groningen. Osteoporos Int 6:213–218PubMed

50.

Carrozzo M, Cantatore FP, Pallante R, Lo SF, D’Amore M, Pipitone V (1985) [Evaluation of the effects of anabolic steroids, calcitonin and 25-hydroxycholecalciferol on the spongy bone of rats]. Rev Rheum Mal Osteoartic 52:17–19

51.

Lindgren U, Lindholm S, Sarby B (1978) Short-term effects of 1-alpha-hydroxy-vitamin D₃ in patients on corticosteroid treatment and in patients with senile osteoporosis. Acta Med Scand 204:89–92PubMed

52.

Lund B, Andersen RB, Friis T, Hjorth L, Jorgensen FS, Norman AW et al. (1977) Effect of 1alpha-hydroxyvitamin D₃ and 1,25-dihydroxyvitamin D₃ on intestine and bone in glucocorticoid-treated patients. Clin Endocrinol (Oxf) 7:177s–181s

53.

Sambrook P (1999) Alfacalcidol and calcitriol in the prevention of bone loss after organ transplantation. Calcif Tissue Int 65:341–343CrossRefPubMed

54.

Kugai N, Koide Y, Kimura S, Yamashita K (1984) Inhibitory effects of active vitamin D preparations on PTH secretion in rats. Endocrinol Jpn 31:151–158PubMed

55.

Liesegang P, Romalo G, Sudmann M, Wolf L, Schweikert HU (1994) Human osteoblast-like cells contain specific, saturable, high-affinity glucocorticoid, androgen, estrogen, and 1 alpha,25-dihydroxycholecalciferol receptors. J Androl 15:194–199PubMed

56.

Tam CS, Wilson DR, Hitchman AJ, Harrison JE (1981) Protective effect on vitamin D₂ on bone apposition from the inhibitory action of hydrocortisone in rats. Calcif Tissue Int 33:167–172PubMed

57.

Sjoden GO, Johnell O, DeLuca HF, Lindgren JU (1984) Effects of 1 alpha OHD₂ on bone tissue. Studies of 1 alpha OHD₂ and 1 alpha OHD₃ in normal rats and in rats treated with prednisolone. Acta Endocrinol (Copenh) 106:564–568

58.

Karatabanova NA, Spirichev VB, Sokolova SV, Bogoslovskii NA (1985) [Effect of 1,25-dioxycholecalciferol and 24,25-dioxycholecalciferol on calcium homeostasis in rats given hydrocortisone in the diet with various phosphorus contents]. Vopr Pitan 2:52–56PubMed

59.

Geusens P, Dequeker J, Nijs J, Verstraeten A, Bramm E (1991) Prevention and treatment of osteopenia in the ovariectomized rat: effect of combined therapy with estrogens, 1-alpha vitamin D, and prednisolone. Calcif Tissue Int 48:127–137PubMed

60.

Turnquist J, Ornoy A, Eini D, Schwartz Z (1992) Effects of 1 alpha(OH)-vitamin D₃ and 24,25(OH)2-vitamin D₃ on long bones of glucocorticoid-treated rats. Acta Anat (Basel) 145:61–67

61.

Aerssens J, van Audekercke R, Talalaj M, Van Vlasselaer P, Bramm E, Geusens P et al. (1994) Effect of 1 alpha-vitamin D₃ on bone strength and composition in growing rats with and without corticosteroid treatment. Calcif Tissue Int 55:443–450PubMed

62.

Andjelkovic Z, Vojinovic J, Pejnovic N, Popovic M, Dujic A, Mitrovic D et al. (1999) Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D₃ in rheumatoid arthritis patients. Clin Exp Rheumatol 17:453–456PubMed

63.

Hirata M, Kato H, Debuchi H, Ikesue A, Mitamura M, Nakagawa H (1994) Anti-inflammatory effect of 22-oxa-1 alpha,25-dihydroxyvitamin D₃ on carrageenin-induced inflammation in rats. Biol Pharm Bull 17:1130–1131PubMed

64.

Inoue M, Matsui T, Nishibu A, Nihei Y, Iwatsuki K, Kaneko F (1998) Regulatory effects of 1alpha,25-dihydroxyvitamin D₃ on inflammatory responses in psoriasis. Eur J Dermatol 8:16–20PubMed

65.

Lempert UG, Minne HW, Albrecht B, Scharla SH, Matthes F, Ziegler R (1989) 1,25-Dihydroxyvitamin D₃ prevents the decrease of bone mineral appositional rate in rats with inflammation-mediated osteopenia (IMO). Bone Miner 7:149–158PubMed

66.

Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R (1994) Activated form of vitamin D [1,25(OH)₂D₃] and its analogs are dose-reducing agents for cyclosporine in vitro and in vivo. Transplant Proc 26:3048–3049PubMed

67.

McFadden RG, Vickers KE, Fraher LJ (1991) Lymphocyte chemokinetic factors derived from human tonsils: modulation by 1,25-dihydroxyvitamin D₃ (calcitriol). Am J Respir Cell Mol Biol 4:42–49PubMed

68.

Mizutani H, Nouchi N, Shimizu M (1998) The downregulation of interleukin 1 and tumour necrosis factor receptors by topical tacalcitol (1,24(OH)₂D₃) in psoriasis. Br J Dermatol 139:536–537CrossRefPubMed

69.

Müller K, Bendtzen K (1992) Inhibition of human T lymphocyte proliferation and cytokine production by 1,25-dihydroxyvitamin D₃. Differential effects on CD45RA+ and CD45R0+ cells. Autoimmunity 14:37–43PubMed

70.

Tsuji M, Fujii K, Nakano T, Nishii Y (1994) 1 alpha-hydroxyvitamin D₃ inhibits type II collagen-induced arthritis in rats. FEBS Lett 337:248–250CrossRefPubMed

71.

van Etten E, Branisteanu DD, Verstuyf A, Waer M, Bouillon R, Mathieu C (2000) Analogs of 1,25-dihydroxyvitamin D₃ as dose-reducing agents for classical immunosuppressants. Transplantation 69:1932–1942CrossRefPubMed

72.

Bijlsma JW, Raymakers JA, Mosch C, Hoekstra A, Derksen RH, Baart dlF et al. (1988) Effect of oral calcium and vitamin D on glucocorticoid-induced osteopenia. Clin Exp Rheumatol 6:113–119PubMed

73.

De Sévaux RG, Hoitsma AJ, Corstens FH, Wetzels JF (2002) Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study. J Am Soc Nephrol 13:1608–1614PubMed

74.

Lambrinoudaki I, Chan DT, Lau CS, Wong RW, Yeung SS, Kung AW (2000) Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study. J Rheumatol 27:1759–1765PubMed

75.

Mirzaei S, Zajicek HK, Knoll P, Hahn M, Levi M, Kohn H et al. (2003) Effect of rocaltrol on bone mass in patients with pulmonary disease treated with corticosteroids. J Asthma 40:251–255CrossRefPubMed

76.

Reginster JY, Kuntz D, Verdickt W, Wouters M, Guillevin L, Menkes CJ et al. (1999) Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 9:75–81CrossRefPubMed

77.

Ringe JD, Coster A, Meng T, Schacht E, Umbach R (1999) Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium. Calcif Tissue Int 65:337–340CrossRefPubMed

78.

Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N et al. (1993) Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 328:1747–1752CrossRefPubMed

79.

Sambrook P, Henderson NK, Keogh A, MacDonald P, Glanville A, Spratt P et al. (2000) Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res 15:1818–1824PubMed

80.

Schaadt O, Bohr H (1986) Alfacalcidol in prednisone treatment—a controlled study of effect on bone mineral content in lumbar spine, femoral neck and shaft. Calcif Tissue Int 39:A58

81.

Stempfle HU, Werner C, Echtler S, Wehr U, Rambeck WA, Siebert U et al. (1999) Prevention of osteoporosis after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation 68:523–530PubMed

82.

Stempfle HU, Werner C, Siebert U, Assum T, Wehr U, Rambeck WA et al. (2002) The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation 73:547–552

83.

Bianda T, Linka A, Junga G, Brunner H, Steinert H, Kiowski W et al. (2000) Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate. Calcif Tissue Int 67:116–121CrossRefPubMed

84.

Diamond T, McGuigan L, Schonell M, Levy S, Rae D (1997) A 2 year open randomized controlled trial comparing calcitriol to cyclical etidronate for the treatment of glucocorticoid-induced osteoporosis. J Bone Miner Res 12:S511

85.

Henderson K, Eisman J, Keogh A, MacDonald P, Glanville A, Spratt P et al. (2001) Protective effect of short-tem calcitriol or cyclical etidronate on bone loss after cardiac or lung transplantation. J Bone Miner Res 16:565–571PubMed

86.

Nam JH, Moon JI, Chung SS, Kim SI, Park KI, Song YD et al. (2000) Pamidronate and calcitriol trial for the prevention of early bone loss after renal transplantation. Transplant Proc 32:1876CrossRefPubMed

87.

Ringe JD, Dorst A, Faber H, Ibach K, Preuss J (2003) Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. Rheumatology (Oxford) 42:743–749

88.

Sambrook PN, Kotowicz M, Nash P, Styles CB, Naganathan V, Henderson-Briffa KN et al. (2003) Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 18:919–924PubMed

89.

Van Cleemput J, Daenen W, Geusens P, Dequeker P, Van De WF, VanHaecke J (1996) Prevention of bone loss in cardiac transplant recipients. A comparison of biphosphonates and vitamin D. Transplantation 61:1495–1499PubMed

90.

Giannini S, Dangel A, Carraro G, Nobile M, Rigotti P, Bonfante L et al. (2001) Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res 16:2111–2117PubMed

91.

Kovaç D, Lindic J, Kandus A, Bren AF (2001) Prevention of bone loss in kidney graft recipients. Transplant Proc 33:1144–1145CrossRefPubMed

92.

Amin S, LaValley MP, Simms RW, Felson DT (1999) The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum 42:1740–1751CrossRef

93.

Amin S, LaValley MP, Simms RW, Felson DT (2002) The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 17:1512–1526PubMed

94.

Papadimitropoulos E, Wells G, Shea B, Gillespie W, Weaver B, Zytaruk N et al. (2002) Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 23:560–569CrossRefPubMed

95.

Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R et al. (1997) Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337:382–387PubMed

96.

Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E et al. (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202–211CrossRef

97.

Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S et al. (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15:1006–1013PubMed

98.

Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB et al. (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285:320–323PubMed

99.

Kleerekoper M, Villanueva AR, Stanciu J, Rao DS, Parfitt AM (1985) The role of three-dimensional trabecular microstructure in the pathogenesis of vertebral compression fractures. Calcif Tissue Int 37:594–597PubMed

100.

Parfitt AM (1992) Implications of architecture for the pathogenesis and prevention of vertebral fracture. Bone 13:S41–S47CrossRef

101.

Lespessailles E, Siroux V, Poupon S, Andriambelosoa N, Pothuaud L, Harba R et al. (2000) Long-term corticosteroid therapy induces mild changes in trabecular bone texture. J Bone Miner Res 15:747–753PubMed

102.

Chappard D, Legrand E, Basle MF, Fromont P, Racineux JL, Rebel A et al. (1996) Altered trabecular architecture induced by corticosteroids: a bone histomorphometric study. J Bone Miner Res 11:676–685PubMed

103.

Borah B, Dufresne TE, Chmielewski PA, Gross GJ, Prenger MC, Phipps RJ (2002) Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res 17:1139–1147PubMed

104.

Aerssens J, van Audekercke R, Talalaj M, Geusens P, Bramm E, Dequeker J (1996) Effect of 1alpha-vitamin D₃ and estrogen therapy on cortical bone mechanical properties in the ovariectomized rat model. Endocrinology 137:1358–1364CrossRefPubMed

105.

Malluche HH, Faugere MC, Friedler RM, Fanti P (1988) 1,25-dihydroxyvitamin D₃ corrects bone loss but suppresses bone remodeling in ovariohysterectomized beagle dogs. Endocrinology 122:1998–2006PubMed

106.

Juni P, Witschi A, Bloch R, Egger M (1999) The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 282:1054–1060PubMed

107.

American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 44:1496–1503CrossRef

108.

Buckley LM, Hillner BE (2003) A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids. J Rheumatol 30:132–138PubMed

Title: Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies
Authors: R. N. J. de Nijs
J. W. G. Jacobs
A. Algra
W. F. Lems
J. W. J. Bijlsma
Publication date: 01-08-2004
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 8/2004
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-004-1614-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D₃ analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2004

Reply to letter by Bendich and Rosenberg

Prevalence and risk factors of distal radius and calcaneus bone mineral density in Korean population

Nutritional and exercise-related determinants of bone density in elite female runners

Benefits of milk powder supplementation on bone accretion in Chinese children

Hospital-treated minimal-trauma rib fractures in elderly Finns: long-term trends and projections for the future

Quantitative ultrasound measurements of bone: measurement error, discordance, and their effects on longitudinal studies